Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07426380 · ClinicalTrials.gov registry record · Phase 1
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
A Phase 1 study of Renal Impairment and Kidney Failure, Chronic, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT07426380 is a Phase 1 study of Renal Impairment and Kidney Failure, Chronic that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 28 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (18% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07426380, a Phase 1 study of Renal Impairment and Kidney Failure, Chronic, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin). For each participant, the study will last about 14 weeks, excluding screening.
Conditions Studied
Interventions
- DRUG LY3841136
Study Locations (2)
Florida
- Floridian Clinical Research, LLC - Miami Lakes
- Omega Research Orlando LLC - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07426380
The ClinicalTrials.gov registry entry for NCT07426380 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (18% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which LY3841136 is the first listed.
NCT07426380 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07426380 about?
NCT07426380 is a clinical study titled "A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function". The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC)...
What is the current status of trial NCT07426380?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2026-02-24. Estimated completion is 2026-10.
What conditions does trial NCT07426380 study?
This clinical trial studies the following conditions: Renal Impairment, Kidney Failure, Chronic, Kidney Disease, Renal Insufficiency, End-Stage Kidney Disease.
What interventions are being tested in trial NCT07426380?
The interventions under investigation include: LY3841136 (DRUG).
Who is sponsoring clinical trial NCT07426380?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07426380 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.